BioPharma Clinical Trials
Pfizer and Astellas Gain Landmark FDA Approval for PADCEV and Keytruda in Cisplatin Ineligible Muscle Invasive Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of ca...
November 24, 2025 | News
Everest Medicines Begins Global Phase I Trial of EVM14 as First Patient Receives Dose in the United States
The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated ...
November 24, 2025 | News
Henlius Therapy Wins Breakthrough Designation as First Immunotherapy Led Perioperative Regimen for Gastric Cancer
The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer p...
November 21, 2025 | News
ReviR Therapeutics Wins CIRM Grant to Advance First in Class Dual Target Therapy for Huntington’s Disease
ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced that it has been awarded a $4....
November 21, 2025 | News
CRScube Acquires Mednet to Build a Unified Global eClinical Platform Across Asia and North America
CRScube has announced the successful acquisition of Mednet, marking a key milestone in its global strategic growth and expansion into the North Ameri...
November 20, 2025 | News
Kazia Reports Initial Immune Complete Response in Stage IV Triple Negative Breast Cancer Under Expanded Access Combination Regimen
Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, announced that a patient with stage IV triple-negative breast canc...
November 20, 2025 | News
AGC Biologics and Repair Biotechnologies Partner to Advance a Novel mRNA Therapy for Atherosclerotic Disease
Partnership leverages AGC Biologics’ cost-effective and dependable cGMP mRNA and LNP capabilities AGC Biologics announced it is partnering w...
November 20, 2025 | News
AbbVie Secures Approval for EPKINLY in Combination With R2 as the First Bispecific Therapy for Relapsed or Refractory Follicular Lymphoma
EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available f...
November 19, 2025 | News
Akeso Receives NMPA Clearance to Initiate Clinical Trials for China’s First Bispecific Antibody for Alzheimer’s Disease
Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expre...
November 18, 2025 | News
Thermo Fisher Scientific Enrolls First Patient in New CorEvitas™ Myasthenia Gravis Real-World Evidence Registry
Thermo Fisher Scientific Inc., the world leader in serving science, announced the enrollment of the first patient in the new PPD™ CorEvitas&tra...
November 18, 2025 | News
Lundbeck Moves Closer to Asian Launch of Vyepti with New Drug Application Accepted in Japan
Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), mark...
November 17, 2025 | News
PRISM BioLab Reaches Initial Milestone in Joint Oncology Research under Agreement with Ono Pharmaceutical
PRISM BioLab, Co. Ltd. ("PRISM") announces that , PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafte...
November 17, 2025 | News
SAS Launches Clinical Acceleration to Modernise Clinical Trial Analytics and Speed Regulatory Submissions
Powered by the data and AI capabilities of SAS Viya, the life sciences solution streamlines drug development to deliver new therapies to patients faster&nb...
November 17, 2025 | News
Lupin Launches Risperidone Long Acting Injectable in the United States with PrecisionSphere Technology
Global pharma major Lupin announced the launch of Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 5...
November 17, 2025 | News
Most Read
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
